Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.19x

Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Cash Flow Reinvestment Rate of 0.19x as of September 2025, reinvesting CN¥54.40 Million (capex CN¥54.40 Million ) from operating cash flow of CN¥281.88 Million. Explore Shaanxi Meibang Pharmaceutical Group Co (605033) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.19x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥54.40 Million
Capex + Investments

Operating Cash Flow

CN¥281.88 Million
CNY

Capital Expenditures

CN¥54.40 Million
CNY

Shaanxi Meibang Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Shaanxi Meibang Pharmaceutical Group Co Ltd across 7 annual periods. Also explore 605033 asset base for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)

Year-by-year capital reinvestment analysis for Shaanxi Meibang Pharmaceutical Group Co Ltd. For live market cap and broader valuation context, see market cap of Shaanxi Meibang Pharmaceutical Group Co .

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 1.92x CN¥539.05 Million CN¥280.40 Million CN¥158.81 Million ▲ +123.3%
2023 0.86x CN¥288.20 Million CN¥334.79 Million CN¥203.69 Million ▼ -24.3%
2022 1.14x CN¥143.69 Million CN¥126.41 Million CN¥109.29 Million ▼ -19.1%
2020 1.40x CN¥105.20 Million CN¥74.88 Million CN¥61.71 Million ▲ +218.4%
2019 0.44x CN¥56.69 Million CN¥128.45 Million CN¥33.78 Million ▼ -78.5%
2018 2.06x CN¥34.86 Million CN¥16.96 Million CN¥34.86 Million ▲ +244.2%
2017 0.60x CN¥17.56 Million CN¥29.41 Million CN¥17.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow